Positive high-level results have been presented by AstraZeneca (LSE: AZN) from the POTOMAC Phase III trial.
The results showed that a year’s treatment with Imfinzi (durvalumab) plus standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy led to a statistically-significant and clinically-meaningful improvement in disease-free survival (DFS) in high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone.
The trial was not statistically powered to formally test overall survival (OS), though a descriptive analysis demonstrated no detriment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze